- Home
- MIRM vs LANC Comparison
MIRM vs LANC Comparison
Compare MIRM & LANC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- LANC
- Stock Information
- Founded
- MIRM 2018
- LANC 1961
- Country
- MIRM United States
- LANC United States
- Employees
- MIRM N/A
- LANC N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- LANC Packaged Foods
- Sector
- MIRM Health Care
- LANC Consumer Staples
- Exchange
- MIRM Nasdaq
- LANC Nasdaq
- Market Cap
- MIRM 1.9B
- LANC N/A
- IPO Year
- MIRM 2019
- LANC N/A
- Fundamental
- Price
- MIRM $38.39
- LANC $190.19
- Analyst Decision
- MIRM Strong Buy
- LANC Buy
- Analyst Count
- MIRM 11
- LANC 4
- Target Price
- MIRM $58.55
- LANC $211.33
- AVG Volume (30 Days)
- MIRM 439.1K
- LANC 166.7K
- Earning Date
- MIRM 05-07-2025
- LANC 04-30-2025
- Dividend Yield
- MIRM N/A
- LANC 2.00%
- EPS Growth
- MIRM N/A
- LANC 21.25
- EPS
- MIRM N/A
- LANC 5.69
- Revenue
- MIRM $336,888,000.00
- LANC $1,900,130,000.00
- Revenue This Year
- MIRM $29.51
- LANC $5.03
- Revenue Next Year
- MIRM $20.27
- LANC $3.31
- P/E Ratio
- MIRM N/A
- LANC $33.22
- Revenue Growth
- MIRM 80.76
- LANC 1.77
- 52 Week Low
- MIRM $23.14
- LANC $163.20
- 52 Week High
- MIRM $54.23
- LANC $202.63
- Technical
- Relative Strength Index (RSI)
- MIRM 32.65
- LANC 63.02
- Support Level
- MIRM $37.83
- LANC $181.55
- Resistance Level
- MIRM $40.32
- LANC $187.81
- Average True Range (ATR)
- MIRM 2.47
- LANC 5.91
- MACD
- MIRM -0.28
- LANC 1.68
- Stochastic Oscillator
- MIRM 17.20
- LANC 96.36
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.